Zacks: Brokerages Anticipate AnaptysBio Inc (NASDAQ:ANAB) Will Post Earnings of -$1.17 Per Share

Wall Street brokerages expect that AnaptysBio Inc (NASDAQ:ANAB) will post ($1.17) earnings per share for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for AnaptysBio’s earnings. The highest EPS estimate is ($0.77) and the lowest is ($1.47). AnaptysBio posted earnings of ($0.66) per share during the same quarter last year, which indicates a negative year over year growth rate of 77.3%. The business is scheduled to report its next quarterly earnings report on Thursday, November 14th.

Zacks’ earnings per share calculations are a mean average based on a survey of analysts that that provide coverage for AnaptysBio.

AnaptysBio (NASDAQ:ANAB) last posted its quarterly earnings results on Thursday, August 8th. The biotechnology company reported ($0.89) earnings per share for the quarter, topping the consensus estimate of ($0.97) by $0.08. The business had revenue of $5.00 million during the quarter. During the same period in the previous year, the company earned ($0.57) earnings per share. The firm’s revenue was up 4900.0% compared to the same quarter last year.



Several equities research analysts have recently issued reports on ANAB shares. ValuEngine upgraded shares of AnaptysBio from a “hold” rating to a “buy” rating in a report on Friday, August 16th. Zacks Investment Research upgraded shares of AnaptysBio from a “sell” rating to a “hold” rating in a research note on Wednesday, August 14th. HC Wainwright set a $126.00 target price on shares of AnaptysBio and gave the stock a “buy” rating in a research note on Monday, June 24th. Credit Suisse Group lowered their target price on shares of AnaptysBio from $79.00 to $75.00 and set a “neutral” rating for the company in a research note on Friday, August 9th. Finally, Stifel Nicolaus set a $63.00 target price on shares of AnaptysBio and gave the stock a “hold” rating in a research note on Monday, August 12th. Three equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. AnaptysBio has an average rating of “Buy” and an average target price of $103.00.

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. FMR LLC lifted its stake in AnaptysBio by 0.9% during the 1st quarter. FMR LLC now owns 4,047,987 shares of the biotechnology company’s stock valued at $295,705,000 after acquiring an additional 35,252 shares during the period. BlackRock Inc. lifted its stake in AnaptysBio by 13.4% during the 2nd quarter. BlackRock Inc. now owns 2,050,390 shares of the biotechnology company’s stock valued at $115,681,000 after acquiring an additional 242,187 shares during the period. Vanguard Group Inc. lifted its stake in AnaptysBio by 3.4% during the 2nd quarter. Vanguard Group Inc. now owns 1,985,144 shares of the biotechnology company’s stock valued at $112,001,000 after acquiring an additional 65,527 shares during the period. Invesco Ltd. lifted its stake in AnaptysBio by 25,030.8% during the 2nd quarter. Invesco Ltd. now owns 1,097,462 shares of the biotechnology company’s stock valued at $61,919,000 after acquiring an additional 1,093,095 shares during the period. Finally, OppenheimerFunds Inc. lifted its stake in shares of AnaptysBio by 0.3% in the 1st quarter. OppenheimerFunds Inc. now owns 1,075,890 shares of the biotechnology company’s stock valued at $78,592,000 after purchasing an additional 3,671 shares during the period.

ANAB stock traded down $2.30 during midday trading on Tuesday, reaching $38.47. 311,707 shares of the company’s stock traded hands, compared to its average volume of 276,212. The stock’s 50-day moving average is $44.34 and its 200 day moving average is $61.84. The stock has a market cap of $1.11 billion, a P/E ratio of -15.39 and a beta of 1.55. AnaptysBio has a 52-week low of $38.29 and a 52-week high of $103.83.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company's products include Etokimab, an anti-interleukin (IL)-33 program for the treatment of atopic dermatitis, eosinophilic asthma, and chronic rhinosinusitis with nasal polyps; ANB019, an anti-IL-36 receptor program for generalized pustular psoriasis and palmo-plantar pustular psoriasis; and anti-inflammatory checkpoint modulators for inflammatory diseases.

Further Reading: What is Depreciation?

Get a free copy of the Zacks research report on AnaptysBio (ANAB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for AnaptysBio (NASDAQ:ANAB)

Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.